Does Bayer Look like a Buy? | equities.com - 0 views
-
Equities Group on 28 Sep 11The late stage studies of Bayer's oncology drug, Alpharadin are impressive to say the least. Designed for the treatment of prostate cancer that spreads to the bones, the drug is able to extend life of late-stage patients while minimizing damage to healthy tissue.